Ribon is a clinical-stage biotechnology company dedicated to the discovery and development of first-in-class small molecule inhibitors to block the fundamental ability of cancer cells to survive under stress.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $155M
Founded date: 2015
Investors 7
| Date | Name | Website |
| - | US Venture... | usvp.com |
| - | Takeda Ven... | takeda.com |
| - | K2 HealthV... | k2healthve... |
| - | The Column... | thecolumng... |
| - | Avego | avego.com |
| - | Vivo Capit... | vivocapita... |
| 30.07.2021 | GV | gv.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 30.01.2023 | - | $25M | - |
| 14.07.2021 | - | $65M | - |
| 04.01.2019 | Series B | $65M | - |
Mentions in press and media 18
| Date | Title | Description |
| 30.01.2023 | Ribon Therapeutics Announces $25 Million Equity Investment from Pfizer | - |
| 20.07.2021 | Digital health news, funding roundup in the prior week; July 18 | With $150B already invested, VC is set to have another recording breaking year With $150B already invested, VC is set to have another recording breaking year. There was $75 billion invested across an estimated 4,302 deals in the second quar... |
| 14.07.2021 | Ribon Therapeutics is looking to break the mold for PARP inhibitors and has a slate of Big Pharma backers on board | Ribon Therapeutics broke three years of radio silence back in early 2019 to spread the word of its $65 million Series B round. Now, two and a half years later, the company’s lead PARP inhibitor has investors reaching a littl... |
| 14.07.2021 | Ribon Therapeutics Secures $65 Million Financing | CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways in cancer and inflammation, announced the closing of a $65 million financing. The financin... |
| 14.07.2021 | Ribon Therapeutics, Inc. announced that it has received $65 million in funding from a group of investors | On July 14, 2021, Ribon Therapeutics, Inc. closed the transaction. The company raised $65,000,000 in funding led by existing investors Deerfield Management Company, L.P. and U.S. Venture Partners along with participation from new investors ... |
| 14.07.2021 | Ribon Therapeutics Secures $65 Million Financing | - |
| 14.07.2021 | Ribon Therapeutics Secures $65 Million Financing | - |
| 14.07.2021 | Ribon Therapeutics : Secures $65 Million Financing | Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways in cancer and inflammation, announced the closing of a $65 million financing. The financing was led by Deerfield Management... |
| 14.07.2021 | Venture capital exit activity hits a record | If it feels as if venture capitalists across the board are congratulating each other on the daily for an initial public offering or acquisition of a portfolio company, you’re not wrong. Paid Content How to ensure your marketers stay dynamic... |
| 14.07.2021 | Venture capital exit activity hits a record | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content How an operational overhaul led this company to success From RPM International If it... |
Show more